Please login to the form below

CAR therapies

This page shows the latest CAR therapies news and features for those working in and with pharma, biotech and healthcare.

FDA approves Roche’s Actemra COVID-19 trial

It was first cleared by the FDA as a treatment for rheumatoid arthritis and has also subsequently been approved in juvenile idiopathic arthritis, giant cell arteritis and CRS associated with ... T cell therapies for cancer.

Latest news

China backs use of Roche’s Actemra for coronavirus

and CRS associated with CAR-T cell therapies for cancer.
GSK pays $50m upfront to tap Immatics’ cell therapy platform

Moreover, unlike currently-approved CAR-T therapies for cancer like Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) which are approved for haematologic cancers, TCRs has the potential to ... Meanwhile, the UK
FDA starts priority review of Kite’s CAR-T for mantle cell lymphoma

One notable side effect of CAR-T therapies is cytokine release syndrome (CRS) – as CAR T cells multiply, they cause huge amounts of chemicals called cytokines to be released into the ... The uptake of CAR-T therapies, however, has proven difficult, as
CRISPR gene-editing in cancer patients is safe, according to new study

June is well-known for his work developing one of the first CAR-T therapies, Novartis’ Kymriah, which he co-invented. ... CAR-T therapies extract a patient’s own white blood cells, and modify them to attack malignant cells.
EMA begins review of Kite’s CAR-T for mantle cell lymphoma

CAR-T therapies work differently to these drugs – in CAR-T therapies, patients’ cells are harvested and modified so they are more likely to seek out and destroy cancer cells expressing ... Uptake of CAR-T therapies can prove difficult, as companies

More from news
Approximately 1 fully matching, plus 86 partially matching documents found.

Latest Intelligence

The impact of COVID-19 on clinical trials

impact on the initiation and completion of hundreds of clinical trials involving investigational therapies for many serious diseases. ... Therapy mechanism of action – immunosuppressive therapies and therapies that require complex and prolonged
Cortellis Drugs to Watch in 2020 report

Thanks to the CAR construct, the engineered T cells can recognise and attack the CD19-expressing cancer cells. ... This composition could confer efficacy and safety advantages, including fewer adverse effects such as cytokine release syndrome (CRS) and
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances

At the spear point is China’s emergence as the epicentre of biotech research and development, with its performance on CAR-T therapies turning heads. ... We are introducing the international best practices of developing CAR T to our China team and
European biotech: a new generation of leaders emerges

year. The promise of the molecule is great, with analysts seeing it as a possible challenge to Novartis and Gilead’s CAR-T therapies. ... This means its clinical outcomes could match those seen in the CAR-Ts, but without the complexity and cost of
The dawn of a new era in medical education

Innovation is not without its challenges. Let’s take haematology as our case study; there has been a flurry of revolutionary cell therapies to treat blood cancers, including CAR-T therapies. ... therapies, where the administration is not as simple as

More from intelligence
Approximately 0 fully matching, plus 27 partially matching documents found.

Latest appointments

Health comms agency emotive hires new cell and gene therapy leader

It is also charged with developing HCP engagement on gene silencing technology and educating on cell therapies such as CAR-T, and the new business unit will provide core expertise in ... He says this will be needed to ensure advanced therapies realise
Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult and more

Ceylad appoints new CFO. Clinical-stage biopharma focused on the development of CAR-T cell therapies has announced that Filippo Petti has been appointed as Chief Financial Officer. ... He said: “Celyad’s differentiated approach to the field of CAR-T

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

In the precision medicine era, the line between products and services is blurred

Instead, we carried out in-depth interviews with different types of stakeholders who had considerable experience working on early CAR-T therapies and clinical trials. ... Both of these scenarios were true in the case of the CAR-T treatment.
Precision paediatrics: Treating patients with CAR-T

It’s an exciting time for CAR-T therapy. SA: It’s an integrated, holistic approach. ... This approach can make targeted therapies like CAR-T a reality. A good example at GOSH is in bone marrow transplants.
Highlights in haematologic malignancy from ASH 2018

However, CAR T-cell therapies stop working in some patients and severe toxicity can also occur. ... Other abstracts reported on CAR T-cell therapies for multiple myeloma directed against the B-cell maturation antigen (BCMA).
Download our infographic: Addressing the biggest challenges for rare disease communities

Recently these have included advanced genetic therapies, such as viral mediated gene transfer and CAR-T therapies.
Training the next generation of biotech leaders

In this year alone, the FDA has taken the groundbreaking step of approving two CAR-T therapies. ... The approval of two CAR-T therapies this year illustrates how cell and gene therapies are turning from scientific dream to reality, with companies in the

More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Surviving cancer: a new era for patients: Now more than ever, a shift in perspective is needed...
Crisis? No problem!: Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?: First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....